AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03334591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apatinib
Description: Apatinib 500mg with Docetaxel 60mg/m2
Study NCT01254292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUD (LCS, BAY86-5028)
Description: LCS12 insertion will occur at randomization visit (Visit 2). Duration of study treatment is 18 months with optional extension to 36 months for subjects in this group only.
Study NCT01254292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yasmin (EE30/DRSP, BAY86-5131)
Description: Combined oral contraceptive (COC; Yasmin; 0.03 mg ethinyl estradiol and 3 mg drospirenone); Subjects will start taking COC at / on the day of visit 2 and continue taking one pill / day without any breaks for the entire study duration of 18 months.
Study NCT01103336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pretreatment with intravenous nicorandil vs. placebo before coronary angiography
Description: * Nicorandil group: Pretreatment with intravenous Nicorandil (Sigmart for injection, Choongwae Pharma, Seoul) 12 mg in 0.9% saline 100 ml over 2 hours starting from 1 hour prior to coronary angiography~* Control group: Pretreatment with intravenous 0.9% saline 100 ml over 2 hours starting from 1 hour prior to coronary angiography
Study NCT01103336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pretreatment with intravenous nicorandil vs. placebo before coronary angiography
Description: * Nicorandil group: Pretreatment with intravenous Nicorandil (Sigmart for injection, Choongwae Pharma, Seoul) 12 mg in 0.9% saline 100 ml over 2 hours starting from 1 hour prior to coronary angiography~* Control group: Pretreatment with intravenous 0.9% saline 100 ml over 2 hours starting from 1 hour prior to coronary angiography
Study NCT05836181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing
Description: Effects of Eye Movement Desensitization and Reprocessing on Anxiety, Depression, Quality of Life, Blood Pressure and Heart Rate Variability in Patients with Hypertension.
Study NCT04432259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 4 mg bid for 4 days
Study NCT04432259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral placebo
Study NCT01479127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-SLV187
Study NCT01479127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Levodopa/Carbidopa
Description: Tablet; contains 100 mg levodopa and 10 mg carbidopa
Study NCT01479127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infusion Pump: CADD-Legacy® 1400 Pump
Description: General infusion pump, manufactured by Smiths Medical (US)
Study NCT01479127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NJ-Tube: Silicon ED Tube
Description: Device used to deliver nutrition/drug to stomach/intestine or to aspirate stomach fluid, manufactured by Create Medic Co., Ltd. (Japan)
Study NCT01479127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptor: Hakko Adaptor
Description: Accessory set for fluid infusion set, consisting of caps, connectors and adapters, etc, manufactured by Hakko Medical (Japan)
Study NCT00003831 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery
Study NCT00003831 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT03868761 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sonoma Rises
Description: All participants will receive the intervention, Sonoma Rises, a mobile app designed by psychologists at the National Center for PTSD for wildfire survivors to facilitate recovery from disaster. Users can access evidence-informed tools to help cope with stress, heal from loss, prioritize self-care, connect with others, manage anger, and track their mood using validated assessments. There are also tools designed just for teens and users are linked to psychoeducation on disaster and health and other mental health resources and services.
Study NCT04225962 — intervention group
Intervention type: OTHER
Intervention: Intimate quality of life questionnaire
Description: Preparation of an intimate quality of life questionnaire
Study NCT03495037 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real World Strategy Training
Description: The key features of the protocol are: i. Participants are actively engaged in selecting their treatment goals. The research clinician will work with the participants to identify five specific, measurable real-world goals using a standardized semi-structured interview, the Canadian Occupational Performance Measure. Three of these will be training goals, two will not be trained but evaluated post-intervention for evidence of generalization and transfer to non-trained tasks; ii. A global problem solving approach is used (Goal- Plan- Do- Check). Participants are guided by the trainer to apply this strategy to their goals.
Study NCT03495037 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial Education
Description: The active comparator uses an information-based format and is designed to engage participants without providing any specific training techniques or strategies. During weekly sessions, participants will receive factual information on brain structure and function, age-related cognitive changes, and general brain health issues and will spend time doing non-specific cognitive exercises including crossword and Sodoku puzzles. Homework will consist of reading assignments related to the session topics.
Study NCT01986946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epidural Catheter - Dilaudid
Description: Placement of an epidural catheter to administer local anesthetic and opioid (dilaudid) to the epidural space will be studied as compared to use of intravenous opioid (dilaudid) for pain control following lumbar spine fusion surgery.
Study NCT01986946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dilaudid
Description: Patients in this arm will receive intravenous patient-controlled opioid analgesia (Dilaudid).
Study NCT02081287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP6
Description: IP6 2,000 -3,000 mg per day given orally in two doses
Study NCT02081287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Dose up to 200 mg per day over 10 weeks
Study NCT04374071 — intervention group
Intervention type: DRUG
Intervention: Methylprednisolone
Description: IV methylprednisolone 0.5 to 1 mg/kg/day in 2 divided doses for 3 days
Study NCT00061347 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fiducial marker placement
Description: Placement of fidicual markers under MRI guidance for localization of radiaiton treatment
Study NCT02527993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucobay (acarbose)
Description: Se arm description
Study NCT02527993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Januvia (sitagliptin)
Description: Se arm description
Study NCT02527993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil HEXAL (verapamil)
Description: Se arm description
Study NCT02527993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Victoza (liraglutide)
Description: Se arm description
Study NCT02527993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Signifor (pasireotide)
Description: Se arm description
Study NCT02527993 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Description: Continuous glucose monitoring will be performed during 6 days of the treatment period.
Study NCT00006228 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SC
Study NCT03013491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Study NCT00006228 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00006228 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02527993 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal tolerance test (MTT)
Description: A meal tolerance test will be performed at the end of the treatment period. The subjects will consume the liquid meal at baseline and blood will be drawn for continuous blood sampling.
Study NCT04674644 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The psychosocial effects of COVID-19 pandemic on dental professionals
Description: Analysing the psychosocial effects of COVID-19 pandemic on dental professionals using the Turkish version of the Fear of COVID-19 and Coronavirus Anxiety Scales
Study NCT01881919 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Address: Nature's Best, Century Place, Tunbridge Wells, Kent, TN2 3BE Phone:+44(0)1892 552030 Email:info@naturesbest.co.uk
Study NCT01881919 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Address: Fagron GmbH\&Co. KG, 22885 Barsbuttel, Germany Phone: +49(0)4067067680
Study NCT02140554 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: lovo-cel
Description: lovo-cel is administered by IV infusion following myeloablative conditioning with busulfan.
Study NCT01219855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1 CTAP101 Capsules- 60µg
Description: 60µg of CTAP101 capsules given once daily for 42 days.
Study NCT01219855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1 CTAP101 Capsules - 90µg
Description: 90µg of CTAP101 capsules given once daily for 42 days.
Study NCT01219855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cohort 1 Matching Sugar Capsule
Description: Placebo capsules given once daily for 42 days.
Study NCT01219855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2 CTAP101 Capsules - 30µg
Description: 30µg of CTAP101 capsules given once daily for 42 days.
Study NCT03013491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Study NCT04316689 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S-488210
Description: S-488210 is a freeze-dried injectable formulation containing the following three peptides, S-488201 (a URLC10-derived peptide), S-488202 (a CDCA1-derived peptide) and S-488203 (a KOC1-derived peptide).
Study NCT04316689 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S-488211
Description: S-488211 is a freeze-dried injectable formulation containing the following two peptides, S-488204 (a DEPDC1-derived peptide) and S-488205 (an MPHOSPH1-derived peptide).
Study NCT01035606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training in goal-directed attention regulation
Description: training in goal-directed attention regulation
Study NCT01035606 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: brain health education
Description: brain health education workshops
Study NCT01035606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: computer-assisted training in goal-directed attention regulation
Description: computer-assisted training in goal-directed attention regulation, with trainer guidance and cognitive games to practice skills
Study NCT03536312 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Thoracic Aortic Surgery
Description: Thoracic aortic surgery to treat thoracic aortic aneurysm
Study NCT01427569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IZN-6D4 Gel
Description: Standard wound therapy plus twice weekly topical application of hydrogel containing botanical extracts.
Study NCT01427569 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo hydrogel
Description: Standard wound therapy plus twice weekly topical application of color-matched placebo hydrogel
Study NCT03596177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: MEDI0382 will be administered subcutaneously, titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period.
Study NCT03596177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered subcutaneously for 16 days in the single-blind treatment period in both MEDI0382 and placebo arms, and SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period in placebo arm.
Study NCT03596177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously for 16 days in the single-blind treatment period in both MEDI0382 and placebo arms, and SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period in placebo arm.
Study NCT02532595 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: manual therapy and exercise
Description: soft tissue mobilization, stretches, concentric and eccentric strengthening
Study NCT02532595 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: manual therapy and exercise
Description: soft tissue mobilization, stretches, concentric and eccentric strengthening
Study NCT02532595 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trigger point dry needling
Description: trigger point dry needling to trigger points located in the gastrocnemius, soleus and tibialis posterior
Study NCT00983450 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: watching a normal walking clip
Description: the study group will gain an intervention consisting of 12 therapy sessions, administered for 12 consecutive days (apart of weekends). The intervention will include 6 minutes of watching a movie clip alternately showing a healthy man and a healthy woman at their sixties, walking while being filmed from various angles. Immediately after watching, the subject will perform 6 minutes of walking, under the experimenters supervision, but without his or hers intervention. Immediately following the walking, the whole procedure will be repeated (watching a clip and walking).
Study NCT00983450 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: watching walk backward clip
Description: The control group will undergo 12 treatments of the same nature, but will watch the movie clip shown backwards, so that the people filmed will seem to walk backwards (it was established that watching a reversed action does not activate the MNS system activated by a regular execution of the activity \[Celnik et al., 2008\]), followed by 6 minutes of walking under the experimenters supervision, then watching the movie again and walking again.
Study NCT02085239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Ropivacaine
Description: * 8-10 ml of Lidocaine given by subcutaneous injection~* 8-10 ml of Ropivacaine given by subcutaneous injection
Study NCT02085239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine alone
Study NCT01497314 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low Lactose Infant Formula
Description: Low Lactose Infant Formula
Study NCT01648608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane for neoadjuvant chemotherapy
Study NCT01675804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized cognitive rehabilitation
Description: - Computerized cognitive rehabilitation: 20 ninety-minute sessions of computerized cognitive rehabilitation.
Study NCT01675804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritalin
Description: -drug therapy: 2 or 3 doses of 10 mg tablets of Immediate-release Methylphenidate (Ritalin) per day for 2 months.
Study NCT01675804 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo CACR [PCACR]
Description: PCACR: 20 ninety-minute sessions of Placebo computerized cognitive training.
Study NCT03344601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: The program will consist of 18 face-to-face coaching sessions (\~1 hour) over 12 months. The timing of these sessions will be decided between participant and coach. A coaching manual will be used to provide a structured approach to coaching sessions, focussing on physical activity engagement (specifically aerobic and strengthening exercise) and adherence to exercise. The intervention will take place in the participant's home or in a rehabilitation facility at the research site. Each participant will be provided with a choice of exercise equipment options (e.g. exercise bike, weights, therabands), gym membership or use of online exercise resources. Participants will develop physical activity goals that will be monitored and adjusted throughout the program. Physical activity diaries will be completed to record the amount and type of physical activity involvement. Wearable activity monitors will also be used to facilitate/monitor physical activity and sedentary behaviours.
Study NCT04238663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB02 (Bevacizumab Biosimilar)
Description: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion
Study NCT04238663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU approved Avastin®
Description: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion
Study NCT04238663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US licenced Avastin®
Description: Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion
Study NCT00787696 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral HIV/STD risk reduction
Description: 18 60-minute group sessions plus 1 individual health and safety planning session
Study NCT00787696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral HIV/STD risk reduction
Description: 18 60-minute group sessions plus 1 individual health and safety planning session
Study NCT00668434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: For participants who weigh 50 kg or more, the prednisone dose will be 60 mg daily for 5 days, then 40 mg daily for 5 days, and then 20 mg daily for 5 days. For participants who weigh less than 50 kg, the dose will be 40 mg daily for 10 days, and then 20 mg daily for 5 days.
Study NCT00668434 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will look the same as the study medication but will not contain active medicine.
Study NCT03362346 — intervention group
Intervention type: DEVICE
Intervention: intracranial pressure monitoring
Description: The patients may have either intracranial pressure (ICP) monitor insertion or external ventricular drainage that can be used as ICP monitor.
Study NCT02402218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care plus peer-mentors
Description: Participants are assigned a peer mentor for support before and after treatment for HCV with Harvoni.
Study NCT02402218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care plus incentives
Description: Participants are given incentives after completing treatment goals.
Study NCT02402218 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants receive standard of care in the clinic from their health care team.
Study NCT01537770 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous vertebroplasty
Description: Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the PMMA reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
Study NCT01537770 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Lidocaine injection
Description: Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. 2 ml of 1% Lidocaine is injected in each needle. Bone cement is prepared on the bench simulating the vertebroplasty-procedure.
Study NCT05784948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Mindfulness Treatment
Description: once a week for 30 minutes, over 8 weeks
Study NCT03561363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-fat diet
Description: The aim of the intervention is to evaluate whether insulin sensitivity and selected Health parameters is affected, when the intake of saturated fatty acids or polyunsaturated fatty acids are highly increased, even when subjects are in energy balance.
Study NCT03830632 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric Training
Study NCT03830632 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Training